Representing Imspex Diagnostics at the forefront of global breath research
Our Senior Research Scientist & Technical Support, Hannah Deane-Cutler, recently attended the International Association of Breath Research (IABR) Summit 2025 in Innsbruck, Austria. The event gathered researchers, clinicians, and industry leaders to share the latest developments in breath analysis across oncology, infectious diseases, gastrointestinal disorders, and next-generation technologies.
Hannah’s participation provided valuable insights that align closely with Imspex’s mission to expand the role of GC-IMS as a practical, clinically relevant technology platform.
Clinical Applications and Early Detection
A key theme at the Summit was the role of breath analysis in the early detection of cancer. Presentations from researchers such as Michael Fadel and George Hanna highlighted how breath biomarkers can support earlier diagnosis, improve patient outcomes while reducing healthcare costs.
Discussions reinforced the importance of disease-specific diagnostic approaches over generalised models, aligning directly with Imspex’s efforts to integrate breath analysis into clinical pathways with precision and reliability.
Infectious Disease Research
Talks by Jane Hill and Haiyang Li explored the use of breath-based biomarkers in diagnosing lung infections and Helicobacter pylori. Notably, new methodologies using nasal exhaled ammonia were shown to differentiate disease states effectively.
These insights point toward opportunities to broaden sampling methods beyond oral breath collection, extending the reach of GC-IMS into wider clinical applications.
Technology and Data Innovation
Advancements in sensor development, gas exchange modelling, and data analytics were presented by speakers including Andreas Güntner, Karl Unterkofler, and Agi Smolinska.
Key takeaways included:
- Development of wearable and continuous monitoring devices for multi-compound detection
- Improved modelling of gas exchange and contamination control for more accurate measurements
- Advanced data handling methods, including ratio-based normalisation and anomaly detection, to ensure robust results in sensitive environments
These directions support Imspex’s ongoing investment in portable GC-IMS instrumentation and sophisticated analytical software, ensuring breath research remains both clinically reliable and commercially scalable.
Looking Ahead
The IABR Summit 2025 showcased the growing momentum of breath analysis worldwide. From wearable sensing platforms to deeper biochemical mapping of volatile compounds, the sector is evolving rapidly and expanding into new fields of application.
Imspex is committed to remaining at the forefront of this progress — providing technology platforms that bridge clinical and industrial needs and ensuring breath analysis reaches its potential as a powerful diagnostic tool.
We thank the IABR community for its collaboration and exchange of ideas, and extend our appreciation to Hannah for representing Imspex at this important event.